
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.

Tyler D. Wagner, PharmD, PhD, is the Director of Research at the National Pharmaceutical Council (NPC), which conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients
As Director of Research, Dr Wagner leads health policy research efforts at NPC, focused on helping decision-makers understand the impact of health policy on patient access and biopharmaceutical innovation.
After completing his PharmD at the University of South Carolina, Dr Wagner worked with the Center for Pharmacy Practice Innovation while earning his PhD in pharmacoeconomics and health outcomes research at Virginia Commonwealth University. Dr Wagner is an author of over 40 manuscripts and abstracts in the field of pharmacy and health policy research.

The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.

As pharmaceutical R&D policies evolve, the authors argue it is crucial to embed American patient values in reimbursement deliberations and frameworks.